论文部分内容阅读
丙氟哌酸是对肠杆菌科(MIC_(90)≤1.0μg/ml),绿脓杆菌(MIC_(90)≤1.0μg/ml)和金葡菌(MIC_(90)≤0.8μg/ml)均具有强大抗菌活性的喹诺酮羧酸抗菌药.本品耐药突变比氨基糖苷类抗生素低,并具有口服吸收良好和半衰期长等优点.本品对52例骨、关节和软组织感染进行临床和细菌评价.治疗方案为口服500mg20例,750mg41例,12小时一次,疗程为5～181日,在治疗期间混合耐药菌感染者联用其他抗菌剂.临床治疗结果表明,在研究期间的分离病原菌包括肠杆菌37株、金葡菌30株和绿脓杆菌21株等在内共92株均清除,分离菌88株(96%)对本品敏感.29例骨髓炎病例,14例经随访一年未见复发;20例皮肤软组织感染中,治愈18(90%),2例分别由于C族链球菌和绿脓杆菌混合耐甲氧西林的金葡菌重复感染而失败;3例关节感染病例中,1例经
Ciprofloxacin is an effective antimicrobial agent against Enterobacteriaceae (MIC_ (90) ≤1.0μg / ml), Pseudomonas aeruginosa (MIC_ (90) ≤1.0μg / ml) and Staphylococcus aureus All have strong antibacterial activity of quinolone carboxylic acid antibacterial drug.This product is more resistant mutations aminoglycoside antibiotics and has good oral absorption and long half-life and other advantages of this product on 52 cases of bone, joint and soft tissue infections for clinical and bacterial Evaluation of the treatment regimen for the oral administration of 500mg20 cases, 750mg41 cases, once every 12 hours, the course of treatment is 5 to 181 days, during the treatment of mixed drug-resistant bacteria infected with other antibacterial agents.Clinical treatment results show that the pathogenic bacteria isolated during the study include Enterobacteriaceae 37, Staphylococcus aureus 30 and Pseudomonas aeruginosa 21 strains, including a total of 92 were cleared, 88 (96%) isolates sensitive to this product.29 cases of osteomyelitis, 14 cases were followed up for one year No recurrence was observed in 20 cases of skin and soft tissue infections, 18 (90%) were cured, 2 cases were due to repeated infections with methicillin-resistant Staphylococcus aureus mixed with Group C streptococci and Pseudomonas aeruginosa, and 3 cases of joint infections , 1 case of